Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Gastrointestinal 1

Conditions

Lymphoma, Large B-Cell, Diffuse 13Lymphoma 13Prostatic Neoplasms 9Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Hodgkin Disease 5Leukemia 4Neoplasms 3Neoplasm Metastasis 3Lymphoma, Non-Hodgkin 3Leukemia, Biphenotypic, Acute 3Burkitt Lymphoma 3Breast Neoplasms 3Recurrence 2Ovarian Neoplasms 2Lymphoma, Follicular 2Lymphoma, B-Cell 2Immunoblastic Lymphadenopathy 2Hemangioma 2Enteropathy-Associated T-Cell Lymphoma 2Stomatitis 1Stomach Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Philadelphia Chromosome 1Peripheral Nervous System Diseases 1Oral Ulcer 1Neurotoxicity Syndromes 1Neoadjuvant Therapy 1Multiple Myeloma 1Metastatic Castration-resistant Prostate Cancer 1Metastatic Castration-Resistant Prostate Cancer Patients 1

Interventions

Gemcitabine 45Cisplatin 34Oxaliplatin 23Capecitabine 17Fluorouracil 13Leucovorin 12pembrolizumab 11lenvatinib 11durvalumab 10S 1 (combination) 10Irinotecan 10Bevacizumab 9apatinib 7Nivolumab 7tremelimumab 6Trastuzumab 5envafolimab 4atezolizumab 4Injections 4Docetaxel 4trametinib 3titanium silicide 3tislelizumab 3irinotecan sucrosofate 3camrelizumab 3Radiotherapy 3Drug Therapy 3zanidatamab 2toripalimab 2surufatinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Biliary Tract Neoplasms × Prednisolone × Clear all
NCT05489211 2026-03-19

Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

AstraZeneca

Phase 2 Recruiting
454 enrolled
GastrointestinalGynecologic

Biliary Tract Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡